A REVIEW OF CAFERGOT DISCONTINUED

talquetamab will increase the level or impact of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. Talquetamab causes cytokine launch syndrome (CRS) that may suppress action of CYP enzymes, resulting in elevated publicity of CYP substrates.ergotamine will enhance the level or outcome of tazemetostat by